Answers are grounded in this paper and cite their sources.
LT4 remains one of the most prescribed medications worldwide, with a disproportionately high initiation and maintenance prescription rate in adults over 60, despite stable overt hypothyroidism (OH) rates. Much of this increase is due to treating subclinical hypothyroidism (SCH), although up to 60% of such cases in older adults are transient.[1] High-quality trials have not demonstrated symptomatic or functional benefits from LT4 in this age group.[2,3,4] Simultaneously, iatrogenic thyrotoxicosis is common among older patients and is consistently associated with atrial fibrillation, fractures, cognitive decline, and higher mortality.[3] The new Dutch prospective deprescribing study and the emerging concept of thyroid hormone deprescribing prompt a reevaluation of what pragmatic, patient-centered LT4 treatment in older adults should entail.[5]
No takes yet. Share an insight, caveat, or question.
Kamrul-Hasan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: